J Korean Diabetes.  2023 Jun;24(2):66-70. 10.4093/jkd.2023.24.2.66.

Assessment of Insulin Secretion and Insulin Resistance

• Park SY

• KMID: 2544518
• DOI: http://doi.org/10.4093/jkd.2023.24.2.66

Abstract

Impaired insulin secretion and increased insulin resistance are major contributors to the pathogenesis of diabetes mellitus (DM). Because pancreatic β-cell function and insulin resistance play an important role in the prevention, diagnosis, treatment, and prognosis of DM, several methods for measuring them have been developed based on dynamic and static tests. Because dynamic tests are time consuming and labor intensive, they are not suitable for use in practice. Static tests are simple and less invasive but do not reflect the complex processes of glucose and insulin metabolism. To easily measure insulin secretion capacity, insulinogenic index calculated from oral glucose tolerance test or mixed meal tolerance test and HOMA-β (homeostasis model assessment for β-cell function) can be used. To assess insulin resistance, HOMA-IR (homeostasis model assessment for insulin resistance) can be used. To measure insulin secretion and insulin resistance more accurately, efficiently, and easily, standardized insulin assay should be establishment and new tests should be continuously developed.

Keyword

Diabetes mellitus; Insulin resistance; Insulin secretion

Reference

1.DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004. 88:787–835. ix.

2.Muniyappa R., Lee S., Chen H., Quon MJ. Current ap-proaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008. 294:E15–26.

3.Finegood DT., Hramiak IM., Dupre J. A modified protocol for estimation of insulin sensitivity with the minimal model of glucose kinetics in patients with insulin-dependent diabetes. J Clin Endocrinol Metab. 1990. 70:1538–49.

4.Bergman RN., Ider YZ., Bowden CR., Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol. 1979. 236:E667–77.

5.DeFronzo RA., Tobin JD., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979. 237:E214–23.

6.Toffolo G., Breda E., Cavaghan MK., Ehrmann DA., Polonsky KS., Cobelli C. Quantitative indexes of beta-cell function during graded up&down glucose infusion from C-peptide minimal models. Am J Physiol Endocrinol Metab. 2001. 280:E2–10.

7.American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2007. 30(Suppl 1):S42–7.

8.Dalla Man C., Campioni M., Polonsky KS., Basu R., Rizza RA., Toffolo G, et al. Two-hour seven-sample oral glucose tolerance test and meal protocol: minimal model assessment of beta-cell responsivity and insulin sensitivity in nondiabetic individuals. Diabetes. 2005. 54:3265–73.

9.Faber OK., Binder C. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Diabetes. 1977. 26:605–10.

10.Matthews DR., Hosker JP., Rudenski AS., Naylor BA., Treacher DF., Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985. 28:412–9.

11.Leighton E., Sainsbury CA., Jones GC. A practical review of C-peptide testing in diabetes. Diabetes Ther. 2017. 8:475–87.

12.Yosten GL., Maric-Bilkan C., Luppi P., Wahren J. Physiolog-ical effects and therapeutic potential of proinsulin C-peptide. Am J Physiol Endocrinol Metab. 2014. 307:E955–68.

13.Jones AG., Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013. 30:803–17.

14.Shen SW., Reaven GM., Farquhar JW. Comparison of im-pedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest. 1970. 49:2151–60.

15.Matsuda M., DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999. 22:1462–70.

16.Stumvoll M., Mitrakou A., Pimenta W., Jenssen T., Yki-Järvin-en H., Van Haeften T, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care. 2000. 23:295–301.

17.Avignon A., Boegner C., Mariano-Goulart D., Colette C., Monnier L. Assessment of insulin sensitivity from plasma insulin and glucose in the fasting or post oral glucose-load state. Int J Obes Relat Metab Disord. 1999. 23:512–7.

18.Gutt M., Davis CL., Spitzer SB., Llabre MM., Kumar M., Czarnecki EM, et al. Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures. Diabetes Res Clin Pract. 2000. 47:177–84.

19.Belfiore F., Iannello S., Volpicelli G. Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. Mol Genet Metab. 1998. 63:134–41.

20.Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol. 1993. 137:959–65.

21.Legro RS., Finegood D., Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998. 83:2694–8.

22.Radziuk J. Insulin sensitivity and its measurement: struc-tural commonalities among the methods. J Clin Endocrinol Metab. 2000. 85:4426–33.